Mechanism-based inhibition of CYP1A1 and CYP3A4 by the furanocoumarin chalepensin

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 3, 2013, Pages 229-238

  Ueng, Yune Fang ^a,b,c   Chen, Chien Chih ^a,d   Yamazaki, Hiroshi ^e   Kiyotani, Kazuma ^f   Chang, Yu Ping ^a   Lo, Wei Shang ^a   Li, Ding Tzai ^g   Tsai, Pei Lun ^g  

^a NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d HUNGKUANG UNIVERSITY   (Taiwan)

^e SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^f RIKEN   (Japan)

^g Mass Solutions Technology Co Ltd   (Taiwan)

Author keywords

Chalepensin; Cytochrome P450; Epoxidation; Hydroxylation; Mechanism based inhibition

Indexed keywords

CHALEPENSIN; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A13; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; FUROCOUMARIN DERIVATIVE; GLUTATHIONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOSOL; DIALYSIS; DRUG DECOMPOSITION; DRUG INTERACTION; ENZYME ANALYSIS; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME KINETICS; EPOXIDATION; HUMAN; IC 50; NONHUMAN; SPECTROPHOTOMETRY;

EID: 84879339923     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-113     Document Type: Article

References (42)

1. Guengerich, F. P.: Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, (ed.): Cytochrome P450. New York, Plenum Press, 1995, pp. 473-535.
2. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F. P.: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270: 414-423 (1994).
3. Wienkers, L. C. and Health, T. G.: Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov., 4: 825-833 (2005).
4. Su, T., Bao, Z., Zhang, Q.-Y., Smith, T. J., Hong, J.-Y. and Ding, X.: Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobaccospecific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res., 60: 5074-5079 (2000).
5. Uno, S., Dalton, T. P., Derkenne, S., Curran, C. P., Miller, M. L., Shertzer, H. G. and Nebert, D. W.: Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. Mol. Pharmacol., 65: 1225-1237 (2004).
6. Di, Y. M., Chow, V. D.-W., Yang, L.-P. and Zhou, S.-F.: Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Curr. Drug Metab., 10: 754-780 (2009).
7. Fukami, T., Nakajima, M., Sakai, H., Katoh, M. and Yokoi, T.: CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin and theophylline. Drug Metab. Dispos., 35: 335-339 (2007).
8. Fukami, T., Katoh, M., Yamazaki, H., Yokoi, T. and Nakajima, M.: Human cytochrome P450 2A13 efficiently metabolizes chemicals in air pollutants: naphthalene, styrene, and toluene. Chem. Res. Toxicol., 21: 720-725 (2008).
9. von Weymarn, L. B., Chun, J. A., Knudsen, G. A. and Hollenberg, P. F.: Effects of eleven isothiocyanates on P450 2A6-and 2A13-catalyzed coumarin 7-hydroxylation. Chem. Res. Toxicol., 20: 1252-1259 (2007).
10. Guo, L.-Q., Taniguchi, M., Xiao, Y.-Q., Baba, K., Ohta, T. and Yamazoe, Y.: Inhibitory effect of natural furanocoumarins on human microsomal cytochrome P450 3A activity. Jpn. J. Pharmacol., 82: 122-129 (2000).
11. Guo, L.-Q., Fukuda, K., Ohta, T. and Yamazoe, Y.: Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab. Dispos., 28: 766-771 (2000).
12. Sekiguchi, N., Higashida, A., Kato, M., Nabuchi, Y., Mitsui, T., Takanashi, K., Aso, Y. and Ishiga, M.: Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. Drug Metab. Pharmacokinet., 24: 500-510 (2009).
13. Mayhew, B. S., Jones, D. R. and Hall, S. D.: An in vivo model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos., 28: 1031-1037 (2000).
14. Anaya, A. L., Macías-Rubalcava, M., Cruz-Ortega, R., García-Santana, C., Sanchez-Monterrubio, P. N., Hernández-Bautista, B. E. and Mata, R.: Allelochemicals from Stauranthus perforatus, a Rutaceous tree of the Yucatan Peninsula, Mexico. Phytochemistry, 66: 487-494 (2005).
15. Stashenko, E. E., Acosta, R. and Martinez, R.: High-resolution gaschromatographic analysis of the secondary metabolites obtained by subcritical-fluid extraction from Colombian rue (Ruta graveolens L.). J. Biochem. Biophys. Methods, 43: 379-390 (2000).
16. de Freitas, T. G., Augusto, P. M. and Montanari, T.: Effect of Ruta graveolens L. on pregnant mice. Contraception, 71: 74-77 (2005).
17. Kong, Y. C., Lau, C. P., Wat, K. H., Ng, K. H., But, P. P. H., Cheng, K. F. and Waterman, P. G.: Antifertility principle of Ruta graveolens. Planta Med., 55: 176-178 (1989).
18. Ueng, Y. F., Chen, C. C., Chung, Y. T., Liu, T. Y., Chang, Y. P., Lo, W. S., Murayama, N., Yamazaki, H., Souček, P., Chau, G. Y., Chi, C. W., Chen, R. M. and Li, D. Z.: Mechanism-based inhibition of CYP2A by chalepensin in recombinant systems, human liver microsomes, and mice in vivo. Br. J. Pharmacol., 163: 1250-1262 (2011). Corrigendum. Br. J. Pharmacol., 165: 2808 (2012).
19. Parikh, A., Gillam, E. M. J. and Guengerich, F. P.: Drug metabolism by Escherichia coli expressing human cytochrome P450. Nat. Biotechnol., 15: 784-788 (1997).
20. Yamanaka, H., Nakajima, M., Fukami, T., Sakai, H., Nakamura, A., Katoh, M., Takamiya, M., Aoki, Y. and Yokoi, T.: CYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab. Dispos., 33: 1811-1818 (2005).
21. Fujieda, M., Yamazaki, H., Kiyotani, K., Muroi, A., Kunitoh, H., Dosaka-Akita, H., Sawamura, Y. and Kamataki, T.: Eighteen novel polymorphisms of the CYP2A13 gene in Japanese. Drug Metab. Pharmacokinet., 18: 86-90 (2003).
22. Alvares, A. P. and Mannering, G. J.: Two-substrate kinetics of drugmetabolizing enzyme systems of hepatic microsomes. Mol. Pharmacol., 6: 206-212 (1970).
23. Phillips, A. H. and Langdon, R. G.: Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization, and kinetic studies. J. Biol. Chem., 237: 2652-2660 (1962).
24. Pohl, R. J. and Fouts, J. R.: A rapid method for assaying the metabolism of 7-ethoxyresorufin by microsomal subcellular fractions. Anal. Biochem., 107: 150-155 (1980).
25. Greenlee, W. F. and Poland, A.: An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin. J. Pharmacol. Exp. Ther., 205: 596-605 (1978).
26. Souček, P.: Novel sensitive high-performance liquid chromatographic method for assay of coumarin 7-hydroxylation. J. Chromatogr. B Biomed. Sci. Appl., 734: 23-29 (1999).
27. Koenigs, L. L., Peter, R. M., Thompson, S. J., Rettie, A. E. and Trager, W. F.: Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab. Dispos., 25: 1407-1415 (1997).
28. Guengerich, F. P., Martin, M. V., Beaune, P. H., Kremers, P., Wolff, T. and Waxman, D. V.: Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem., 261: 5051-5060 (1986).
29. Peter, R., Böcker, R., Beanue, P. H., Iwasaki, M., Guengerich, F. P. and Yang, C. S.: Hydroxylation of chlorzoxazone as a specific probe for human liver microsomal P450 IIE1. Chem. Res. Toxicol., 3: 566-573 (1990).
30. Yamazaki, H., Inoue, K. and Shimada, T.: Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P450 2C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Xenobiotica, 28: 103-115 (1998).
31. Habig, W. H., Pabst, M. J. and Jascoby, W. B.: Glutathione S-transferase: the first enzymatic step in mercapturic acid formation. J. Biol. Chem., 249: 7130-7139 (1974).
32. Lowry, O. H., Roseborough, N. J., Farr, A. L. and Randall, R. L.: Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193: 265-275 (1951).
33. Omura, T. and Sato, R.: The carbon monoxide-binding pigment of liver microsomes. l. Evidence for its hemeprotein nature. J. Biol. Chem., 239: 2370-2378 (1964).
34. Silverman, R. B.: Mechanism-based enzyme inactivators. Methods Enzymol., 249: 240-283 (1995).
35. Emery, M. G., Jubert, C., Thummel, K. E. and Kharasch, E. D.: Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans. J. Pharmacol. Exp. Ther., 291: 213-219 (1999).
36. Renwick, A. B., Watts, P. S., Edwards, R. T., Barton, P. T., Guyonnet, I., Price, R. J., Tredger, J. M., Pelkonen, O., Bobbis, A. R. and Lake, B. G.: Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab. Dispos., 28: 1202-1209 (2000).
37. Nims, R. W., Prough, R. A. and Lubet, R. A.: Cytosol-mediated reduction of resorufin: a method for measuring quinone oxidoreductase. Arch. Biochem. Biophys., 229: 459-465 (1984).
38. Kunze, K. L. and Trager, W. F.: Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol., 6: 649-656 (1993).
39. Kharasch, E. D., Hankins, D. C. and Taraday, J. K.: Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity. Drug Metab. Dispos., 28: 28-33 (2000).
40. de Wolff, F. A. and Thomas, T. V.: Clinical pharmacokinetics of methoxsalen and other psoralens. Clin. Pharmacokinet., 11: 62-75 (1986).
41. Zhou, S., Chan, E., Lim, L. Y., Boelsterli, U. A., Li, S. C., Wang, J., Zhang, Q., Huang, M. and Xu, A.: Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr. Drug Metab., 5: 415-442 (2004).
42. Goosen, T. C., Cillié, D., Bailey, D. G., Yu, C., He, K., Hollenberg, P. F., Woster, P. M., Cohen, L., Williams, J. A., Rheeders, M. and Dijkstra, H. P.: Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. Clin. Pharmacol. Ther., 76: 607-617 (2004).